ERBB2 and breast cancer: Trastuzumab, effective in about 15% of women with breast cancer, targets Human Epidermal Growth Factor Receptor 2 (HER2) and downregulates signaling through Akt/phosphoinositide 3-kinase (PI3K) and MAPK pathways.